Nicotine Induces Podocyte Apoptosis through Increasing Oxidative Stress

Xiqian Lan1*, Rivka Lederman1, Judith M. Eng1, Seyedeh Shadafarin Marashi Shoshtari1, Moin A. Saleem2, Ashwani Malhotra1, Pravin C. Singhal1*

1 Renal Molecular Research Laboratory, Feinstein Institute for Medical Research, Hofstra North Shore LIJ Medical School, New York, United States of America, 2 Academic Renal Unit, Southmead Hospital, Bristol, United Kingdom

* xlan@northwell.edu (XL); psinghal@northwell.edu (PS)

Abstract

Background

Cigarette smoking plays an important role in the progression of chronic kidney disease (CKD). Nicotine, one of the major components of cigarette smoking, has been demonstrated to increase proliferation of renal mesangial cells. In this study, we examined the effect of nicotine on podocyte injury.

Methods

To determine the expression of nicotinic acetylcholine receptors (nAChR subunits) in podocytes, cDNAs and cell lysate of cultured human podocytes were used for the expression of nAChR mRNAs and proteins, respectively; and mouse renal cortical sections were subjected to immunofluorescent staining. We also studied the effect of nicotine on podocyte nephrin expression, reactive oxygen species (ROS) generation (via DCFDA loading followed by fluorometric analysis), proliferation, and apoptosis (morphologic assays). We evaluated the effect of nicotine on podocyte downstream signaling including phosphorylation of ERK1/2, JNK, and p38 and established causal relationships by using respective inhibitors. We used nAChR antagonists to confirm the role of nicotine on podocyte injury.

Results

Human podocytes displayed robust mRNA and protein expression of nAChR in vitro studies. In vivo studies, mice renal cortical sections revealed co-localization of nAChRs along with synaptophysin. In vitro studies, nephrin expression in podocyte was decreased by nicotine. Nicotine stimulated podocyte ROS generation; nonetheless, antioxidants such as N-acetyl cysteine (NAC) and TEMPO (superoxide dismutase mimetic agent) inhibited this effect of nicotine. Nicotine did not modulate proliferation but promoted apoptosis in podocytes. Nicotine enhanced podocyte phosphorylation of ERK1/2, JNK, and p38, and their specific inhibitors attenuated nicotine-induced apoptosis. nAChR antagonists significantly suppressed the effects of nicotine on podocyte.
Conclusions
Nicotine induces podocyte apoptosis through ROS generation and associated downstream MAPKs signaling. The present study provides insight into molecular mechanisms involved in smoking associated progression of chronic kidney disease.

Introduction
It is estimated that there are more than a billion cigarette smokers all over the world, and over one third of them above 15 years of age [1, 2]. Cigarette smoking has been well known critical risk factor for various diseases including lung, cardiovascular, and cancer. Clinical reports have demonstrated that cigarette smoking plays important role in the progression of chronic kidney disease (CKD), and it worsens CKD in patients with diabetes, hypertension, polycystic kidney disease, and post kidney transplant [2–4]. In addition, smoking may cause “de novo” renal injury to those people who are healthy and have no pre-existing CKD [2, 5–12].

Among the thousands of compounds present in the tobacco smoking, nicotine has obtained special attention since it is regarded to be responsible for both the addictive properties of tobacco smoking and a variety of biological effects that may play an important role in the pathogenesis of different conditions [2, 13]. Nicotine plays its effects via the activation of the nicotinic acetylcholine receptors (nAChRs) [2, 11]. Both in vitro and in vivo studies demonstrated that nAChRs expressed by mesangial cells contribute to the proliferation of mesangial cells in response to stimulation by nicotine [14, 15]. nAChRs also exist in proximal tubular cells, and their interaction with nicotine results in apoptosis or epithelial-mesenchymal transition (EMT) of these cells [16–18].

Podocytes are terminally differentiated and highly specialized epithelial cells in the Bowman’s capsule in the kidneys. They wrap around capillaries of the glomerulus, and extend foot processes to form a blood urine filtration barrier. Most of the proteinuric diseases are associated with podocytopathy (altered podocyte phenotype; reduction in number and effacement of foot processes) [19, 20]. The presence of nAChRs in podocyte has not been evaluated; moreover, the effect of nicotine on podocytes has not been studied yet. In this study, we examined the effect of nicotine podocyte apoptosis and the involved mechanism.

Materials and Methods
Animal
FVB/N mice were purchased from Jackson Lab (Bar Harbor, ME, USA), and were housed within the rodent holding facilities in the Feinstein Institute for Medical Research (Northwell Health) in Manhasset, New York. All animal procedures and protocols were approved by the Institutional Animal Care and Use Committee (IACUC, approval #2009–012) at the Feinstein Institute. It is under temperature, light and humidity control. Adequate food, water, and bedding are provided. Two male and two female mice at 8 weeks old were used in this study. Mice were sacrificed by carbon dioxide asphyxiation and death was confirmed by cervical dislocation.

Reagents
Nicotine, N-acetyl-L-cysteine (NAC), and 2,2,6,6-Tetramethyl-1-piperidinylxyloxy, free radical, 2,2,6,6-Tetramethylpiperidine 1-oxyl (TEMPO), methyllycaconitine citrate (MLA),
mecamylamine hydrochloride (MEC), VAS2870 (VAS), were purchased from Sigma-Aldrich (St. Louis, MO). SP600125 and SB203580 were purchased from Santa Cruz Biotechnology (Dallas, TX), and PD98059 was from Cell Signaling Technology (Danvers, MA).

Culture of human podocytes

Conditionally immortalized human podocytes were provided by Dr. Moin A. Saleem (Academic Renal Unit, Southmead Hospital, Bristol, UK), and were cultured as discussed in our previous work [21, 22]. Briefly, immortalized human podocytes proliferated in the growth medium containing RPMI 1640 supplemented with 10% fetal bovine serum, 1 X penicillin-streptomycin, 1 mM L-glutamine, and 1 X insulin, transferrin, and selenium (ITS) (Invitrogen, Grand Island, NY) at permissive temperature (33˚C). When the cells reached about 80% confluence, they were transferred to 37˚C for differentiation in a medium without ITS for 6 days. Before nicotine treatment, the differentiated human podocytes were cultured in RPMI 1640 medium with 1% FBS for 12 h. Nicotine were added into the same medium, and then were used to treat podocyte.

RT-PCR

Total RNA was isolated from human podocytes using Trizol reagent (Invitrogen). Five micrograms of total RNA were reverse transcribed using the first-strand synthesis system (Invitrogen). PCR was performed by using Platinum PCR SuperMix High Fidelity (Invitrogen). Sequences of primers for human nAChR subunits were listed in Table 1. GAPDH was used as internal control, and its forward primer was CCATGGAGAAGGC TG, and reverse primer was CAAAGTTGTCATGGATGA. Amplification was performed at 95˚C for 5 min, followed by 30 cycles at 94˚C for 1 min, 55˚C for 30 s, 68˚C for 30 s with a final extension cycle for 5 min at 68˚C. DNA samples were visualized by 2% agarose gel electrophoresis.

Western blotting analysis

Western blotting was performed using established methodology [22]. Briefly, cells were washed with PBS and lysed in RIPA buffer (1 X PBS, pH7.4, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 1.0 mM sodium orthovanadate, 10 μl of protease inhibitor cocktail (100 x, Calbiochem) per 1 ml of buffer, and 100 μg/ml PMSF). Proteins (20–30 μg) were separated by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and then transferred on an Immuno-Blot polyvinylidene fluoride (PVDF) membrane (Bio-Rad, Hercules, CA). After blocking in PBS/Tween (0.1%) with 5% nonfat milk, the membrane was incubated with primary antibodies overnight at 4˚C followed by horseradish peroxidase-conjugated secondary antibodies (Santa Cruz, 1:3000) and then developed using Enhanced Chemiluminescent (ECL) solution (Pierce). Primary antibodies used were rabbit anti-nephrin (Abcam, 1:1000), goat anti-nAChR α5, α6, α7, β3 receptors (Santa Cruz, 1:1000), rabbit anti-cleaved caspase-3 (Cell Signaling, 1:1000), rabbit anti-Bax (Santa Cruz, 1:1000), rabbit anti-Bcl-2 (Santa Cruz, 1:1000), and goat anti-actin (Santa Cruz, 1:3000). For protein expression quantification, the films were scanned with a CanonScan 9950F scanner and the acquired images were then analyzed using the public domain NIH image program (http://rsb.info.nih.gov/nih-image/).

Immunofluorescent microscopy

Immunofluorescent microscopy was performed as discussed in our previous work [22]. Briefly, the kidneys were perfused in situ and then fixed with fresh 4% PFA and stored at -80˚C. Subsequently, paraffin sections (4 μm) were prepared and de-paraffinized in xylene and
re-hydrated through graded concentrations of alcohol. Epitope retrieval was carried out by heating the samples at 98˚C for 2 h in Retrieveall-1 (Signet Laboratories, Inc.). Subsequently, cooled samples were permeabilized with 0.3% triton X-100 for 10 min, and were blocked with 2% BSA in 0.1% triton X-100 for 1 h at room temperature. Sections were then incubated with primary antibodies overnight at 4˚C, followed by Alexa Fluor secondary antibodies (Invitrogen, 1:800), donkey anti-rabbit IgG Alexa Fluor 568 or donkey anti-goat IgG Alexa Fluor 488, for 1 hour at room temperature. Primary antibodies included goat anti-nAChR α5, α6, α7, β3 receptors (Santa Cruz, 1:100), rabbit anti-synaptopodin (Santa Cruz, 1:100). All antibodies were diluted in 0.1% Triton X-100, 2% BSA in PBS. Cells were then counterstained with DAPI to identify nuclei (Sigma-Aldrich). Morphological changes were visualized and captured with a ZEISS microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany) equipped with a digital imaging system.

**Ki-67 staining**

Human podocytes (5 x 10⁴) were planted in 35 mm dishes, and were differentiated for 6 days before use. After appropriate treatment, immunofluorescent staining was performed as previously report [23]. Briefly, the medium was removed, and the cells where successively fixed with 4% PFA, permeabilized with 0.3% triton X-100, and were blocked with 2% BSA in 0.1% triton X-100. Then, the cells were incubated with primary antibody, rabbit anti-Ki-67 (Santa Cruz, 1:100), overnight at 4˚C, followed by Alexa Fluor secondary antibodies (Invitrogen, 1:800), donkey anti-rabbit IgG Alexa Fluor 568 for 1 hour at room temperature. Nuclei were stained with Hoechst 33342. Staining results were visualized and captured with a ZEISS microscope, and Ki-67 positive cells were counted.

**Apoptotic cell determination**

We detected apoptotic cells by using Hoechst taining, following former reports [24, 25]. Briefly, after appropriate treatment, the culture media was removed, and the cells were fixed with 4% PFA for 15 min. After that, Hoechst 33342 (10 μg/ml) was added. After 10 min, cell images were taken with a ZEISS microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany) equipped with a digital imaging system. Apoptotic cells were identified as nucleus condensed and fragmented.

---

**Table 1. Primer sequences for Nicotine receptor subunits (nAChRs).**

| Subunit | Forward primer | Reverse primer |
|---------|----------------|----------------|
| α2      | ACCAAATGTAGCCACCAAGC | AGAACAATGCTGGGGATCCAG |
| α3      | ATGCTGTGCCTCTCTCTTG | ACGTCAATCACATGGCAAC |
| α4      | GCGGTCCAGTAATGGGAGAC | CGTGGCTCCTCCTAGATCAAGC |
| α5      | GGAGTGCGCGGTCGATGCTAT | CGAGAACAAAGGAGGAGAGA |
| α6      | GCACCTCCTGCTGAGTTGAGA | GCCTTCAGTTCCAAATCAC |
| α7      | GTGTTGGTGGACATGGATCGT | CTCTTCAATCAGCAGAGAAGC |
| α9      | CATCCTGTGGCCCTGACTGT | ATGATGGTCAACGGCAGGAG |
| α10     | ACTCAACCGAGAAGGAGTTCG | CACTGGGACACAGTAAAGAG |
| β2      | TTCATCGCAGACCAAGATGC | AGGGCTCACTTCGAGGCT |
| β3      | CCCACAGGAAGAGGAGGAGTCA | CCACAGGGAAGATTCGGCAAG |
| β4      | GAGGTTCGCGAGGATGTCG | CGCATGCTTGCTGAGGAGG |

---

10.1371/journal.pone.0167071.t001
Intracellular ROS measurement

Human podocytes were differentiated in 96-well plates for 6 days as mentioned above, and were then cultured in serum free medium for 12 h. Subsequently, 0.1 to 10 μM nicotine was added. After incubation for another 12 h, intracellular ROS generation was determined by measuring the fluorescence intensity as discussed in our previous work [22].

Statistical analyses

Data were presented as means ± standard deviation (SD) unless otherwise noted. All experiments were repeated at least three times with duplicate or triplicate samples in each assay. All data were evaluated statistically by the analysis of variance (ANOVA), followed by Newman-Keuls multiple comparison tests using software (Prism 4.0, GraphPad Software). In the case of single mean comparison, data were analyzed by t test. P values < 0.05 were regarded as statistically significant.

Results

Nicotinic acetylcholine receptors are expressed in podocyte

Nicotinic acetylcholine receptors (nAChR subunits) have been reported to express in kidney mesangial cells and tubular cells [14–18], but their expression in podocytes has not been studied. Therefore, firstly we examined the expression of nAChR subunits in podocytes. In vitro study, we conducted RT-PCR analysis by using human podocytes as the RNA source. The results revealed higher level expression of nAChR α5, α6, α7, α10, and β4 in human podocytes, but the expression of nAChR α3, α9, β2, and β3 were relatively lower (Fig 1A). Meanwhile, we found that the expression of nAChR α2 and α4 were barely detectable (Fig 1A).

We then collected the cell lysate from human podocyte, and performed Western blotting to examine the protein expression of nAChR subunits. Results showed that α7 expressed at a higher level, whereas α5, α6, and β3 expressed at relatively lower levels (Fig 1B).

To confirm this observation in vivo studies, we performed immunofluorescence staining for nAChR α5, α6, α7, and β3 in mouse renal cortical sections. Results showed that all these three subunits were highly expressed in glomerular, and they were also partially co-localized with synaptopodin, a podocyte marker (Fig 1C). Combined together, these results demonstrate that podocytes display expression of nicotine receptors.

Nicotine causes podocyte injury

To test whether nicotine causes podocyte injury, we treated human podocytes with 1 and 10 μM nicotine for 48 h, and then collected the cell lysate for Western blotting for evaluation of nephrin expression, one of the most important constituents of slit diaphragm. The results showed that nicotine decreased the expression of nephrin in a dose-dependent manner (Fig 2); these findings confirmed the role of nicotine in the induction of podocyte injury.

Nicotine doesn’t increase podocyte proliferation

Nicotine has been demonstrated to increase the proliferation of renal mesangial cell [4]. To detect whether it has similar function on podocyte, we treated differentiated human podocyte with 0.1, 1, and 10 μM nicotine for 3 days, and then examined the changes of cell numbers by cell counting. Results showed that the total cell numbers didn’t significantly change after nicotine treatment (data not shown). To further confirm this observation, we performed immunofluorescent staining to test the changes of Ki-67 positive cell ratio. Results showed that the Ki-
Fig 1. Nicotine receptor subunits (nAChRs) are expressed in podocytes. A. Total RNAs were prepared from differentiated human podocytes, and were used for RT-PCR to detect the expression of nAChR subunits. GAPDH was used as internal control. B. Cell lysate was collected from differentiated human podocytes, and was subjected to Western blotting to detect the expression of nAChRs. C. Paraffin sections were prepared from 2-month-old mice kidneys, and immunofluorescence staining was performed to detect the expression of nAChR subunits. Synaptopodin was used as a marker of podocytes.

doi:10.1371/journal.pone.0167071.g001

Fig 2. Nicotine decrease nephrin expression in podocyte. Differentiated human podocytes were treated with nicotine (1 and 10 μM) for 48 h. Cell lysates were then collected and subjected for Western blotting to detect nephrin expression. A. Representative gels are displayed. B. Quantification of the expression of nephrin in A, and the results (mean ± SD) represent three independent samples. * p < 0.05 compared with control (0 μM).

doi:10.1371/journal.pone.0167071.g002
67 positive cell ratios among the treatments didn’t significantly change (data not shown). Combined together, these indicate that nicotine doesn’t promote podocyte proliferation.

Nicotine increases podocyte apoptosis

Then, we tested whether nicotine causes apoptosis to podocyte. We treated human podocytes with 0.1, 1, and 10 μM nicotine, and then examined the apoptotic cells by Hoechst staining. We observed that apoptotic cells were barely observed after 24 h, and there was no obvious difference among these treatments (data not shown). However, after 48 h, we observed different apoptotic cell ratios. At 0.1 μM, nicotine increased podocyte apoptosis but the result was not statistically significant; when the concentration reached to 1–10 μM, apoptotic cell ratio dramatically increased. These results indicate that nicotine induces podocyte apoptosis in a dose-dependent manner (Fig 3A and 3B).

We also examined whether nicotine could affect apoptosis related proteins. Caspase-3 plays the key role in apoptosis, and its cleaved active peptide has been used as the biomarker of apoptosis. To further confirm the effect of nicotine on podocyte apoptosis, we collected the cell lysate after nicotine treatment, and performed Western blotting. Results showed that nicotine increased the cleaved caspase-3 expression (Fig 4). In addition, nicotine increased the expression of Bax, a pro-apoptotic enzyme; conversely, nicotine decreased Bcl-2, an anti-apoptotic enzyme (Fig 4). Taken together, these results clearly demonstrate that nicotine increase podocyte apoptosis.

Nicotine induces podocyte apoptosis through ROS generation

Our group and others have demonstrated that ROS is a significant contributing factor for podocyte injury and for the progression of chronic kidney disease [22, 26–28]. ROS has
been shown to increase podocyte apoptosis [28–31]. To examine the effect of nicotine on intracellular ROS production, the fluorescence intensity of the intracellular fluoroprobe (DCFH) was evaluated. Results showed that at low concentrations, such as 0.01 and 0.1 μM, nicotine stimulated ROS generation slowly; while, when the concentration reached 1–10 μM, ROS generation was quickly increased when compared with non-treated cells (Fig 5A). Nicotine increased ROS generation in a dose-dependent manner. To detect whether nicotine-induced ROS generation is through the activation of NADPH oxidases, we pre-treated the human podocytes with NADPH oxidase specific inhibitor VAS2870, followed by treatment with nicotine. VAS2870-pretreated podocytes didn’t increase ROS generation (Fig 5B), indicating that nicotine increased ROS generation through the activation of NADPH oxidases.

To determine whether nicotine-induced apoptosis is through ROS generation, the podocytes were pre-treated with ROS scavengers either NAC or TEMPO, and then incubated in media containing 10 μM nicotine. After 24 h, the cells were fixed with PFA, and the apoptotic cells were counted following the Hoechst staining, as mentioned in Materials and Methods. As shown in Fig 6A, pretreatment of the human podocytes with NAC or TEMPO significantly attenuated nicotine-induced podocyte apoptosis. We also performed Western blotting to detect the changes of cleaved caspase-3 expression, and found that addition NAC or TEMPO decreased the its expression (Fig 6B and 6C). Taken together, these data suggest that nicotine-induced ROS generation may be a contributor to the podocyte apoptosis.
MAPK kinase pathways are involved in nicotine-induced podocyte injury

MAPK kinases, including JNK, ERK1/2 and p38 have been implicated in podocyte injury and the progression of chronic kidney diseases (CKD) [32–36]. To examine the involvement of these kinases and factors in nicotine-induced podocyte apoptosis, we first evaluated the phosphorylation of these proteins. We treated human podocytes with 0.1 μM nicotine, and collected the cell lysates at different time points for Western blotting studies. Results showed that nicotine stimulation significantly activated ERK1/2, JNK, and p38 at early time points (Fig 7A). We repeated this experiment with 1 or 10 μM nicotine, and obtained similar results, but the extents of phosphorylation were stronger (data not shown).

To examine the role of activation of MAPK kinases in nicotine-induced apoptosis, apoptotic cell ratios of podocyte were measured after the treatment with nicotine in the presence or absence of SP600125, an inhibitor of JNK, PD98059, an inhibitor of ERK1/2, or SB203580, an inhibitor of p38. As presented in Fig 7B, all these inhibitors partially attenuated nicotine-induced apoptosis. These results indicate that JNK, ERK1/2 and p38 pathways are involved in the regulation of nicotine-induced podocyte apoptosis.

nAChR α7 subunit plays an important role in nicotine-induced podocyte injury

To determine the role of nAChR α7 in the nicotine-induced podocyte injury, we pre-treated human podocytes with either MLA (a nAChR α7 specific antagonist) or MEC (a non-specific
nicotinic acetylcholine receptor antagonist) followed by treatment with nicotine. We found that both antagonists significantly blocked nicotine-induced phosphorylation of p38 (Fig 8A). Interestingly, MEC could completely block nicotine-induced ROS generation as well as induction of apoptosis; on the other hand, MLA blocked these effects partially but significantly (Fig 8B and 8C). These results suggest that nAChR α7 plays an important role in nicotine-induced podocyte injury, and other receptor subunits may also be involved.

Discussion

Podocytes play a vital role in the prevention of glomerular protein leakage during physiological and pathological processes through formation of slit diaphragm [37–40]. Clinical reports have demonstrated that smoking worsens the chronic kidney diseases, and enhances proteinuria [2–12]. Therefore, it is likely that contents of the tobacco smoke directly affect the podocytes. In this study, analysis of RT-PCR, Western blotting, and immunofluorescent staining revealed the expression of several nAChR subunits by podocytes. Nicotine decreased nephrin expression in podocytes, indicating that it caused cell injury to these cells. Nicotine enhanced podocyte oxidative stress resulting into their apoptosis. Nicotine-induced podocyte apoptosis was regulated by the activation of the stress kinase pathways including JNK, ERK, and p38. To our knowledge, this is the first report highlighting the effect of nicotine on podocyte injury.
Nicotine mediates its effects via the activation of muscle and neuronal nicotinic acetylcholine receptors (nAChRs), which are composed of five subunits and expressed by neuronal as well non-neuronal cells [2, 11]. Jaimes et al demonstrated the presence of the nAChRs subunits α4, α5, α7, β2, β3 and β4 in human mesangial cells [4], and Kim et al reported that nAChRs subunits α3, α5, and β1 are expressed in renal proximal tubular epithelial cells (HK-2) [18]. In this study, we found that the mRNAs of subunits α3, α5, α6, α7, α10, β2, β3 and β4 are expressed in human podocytes. Western blotting and immunofluorescent studies displayed that at least 4 types of these subunits including, α5, α6, α7, and β3 are expressed in podocytes. The different expression profiles of the nAChRs subunits may induce cell dependent effects in response to nicotine types of renal cells. For example, 6 nAChRs subunits are expressed in mesangial cells, but only α4, α7 and β4 contributed to nicotine-induced proliferation, and amongst these subunits, α7 subunit played a major role [4]. Similarly, the subunit α7 subunit has been identified as one of the most important for several of the cholinergic actions mediated by nAChRs in macrophages, vascular smooth muscle cells and cancer cell lines [2, 41, 42]. In the present study, we also found that blocking α7 subunit with MLA significantly attenuated nicotine-induced p38 phosphorylation, ROS generation, and cell apoptosis, indicating that this subunit also plays an important role in nicotine-mediated podocyte injury. However, MLA could not completely suppress nicotine-induced ROS generation and apoptosis, suggesting that other subunits may also be involved; this aspect worth investigating in future studies.

Nicotine has been demonstrated to increase proliferation of renal mesangial cell as well as several other cell types [4, 43–46]. In this study, we treated human podocytes with nicotine for 3 days, but didn’t observe obvious changes on the cell numbers; and immunofluorescent staining results showed that Ki-67 positive cell ratios didn’t change after nicotine treatment. These
results indicate that nicotine doesn’t cause podocyte proliferation. Nicotine has also been reported to induce apoptosis in various cells [18, 47, 48]. Consistent with these reports, we found that nicotine increased the number of apoptotic cells and enhanced the expression of apoptotic protein markers including cleaved caspase-3. In addition, nicotine increased the expression of pro-apoptotic protein Bax and decreased the anti-apoptotic protein Bcl-2. These results strongly suggest that nicotine induces podocyte apoptosis.

Nicotine induces ROS generation in a variety of cells and it contributes to the net oxidative stress imposed by cigarette smoking [4, 16, 18, 49, 50]. In previous reported studies, nicotine has been demonstrated to increase the production of ROS generation in culture mesangial cells and stimulated their proliferation and fibronectin production [4, 15]. In this study, we found that nicotine treatment of human podocyte caused a dose-dependent increase in ROS generation, but it didn’t stimulate the proliferation. On the other hand, the increased ROS generation promoted apoptosis in human podocytes, and this effect of nicotine could be
attenuated by NAC and TEMPO. Notably, ROS has been incriminated for apoptosis in multiple instances [28–31]. These findings indicate that podocytes behave differently from mesangial cells in nicotine milieu. One possible reason is that podocytes are highly differentiated epithelial cells, and are more vulnerable to increased oxidative stress when compared with mesangial cells, which robustly proliferate on exogenous stimulation. Nicotine also increases the ROS generation in proximal tubule cells, but the consequences are controversial. Arany et al reported that nicotine potentiate the effects of TGF-β on α-SMA, vimentin and fibronectin production in proximal tubule cells, indicating that nicotine promotes epithelial-mesenchymal transition (EMT) of these cells [16–17]. On the other hand, recently Kim et al reported that nicotine induced apoptosis to renal proximal tubular cells (HK-2 cells) [18]. It’s worth noting that in both studies, they used 200–400 μM of nicotine, which is much higher than the peak concentrations found in the plasma of active smokers [51]. Investigating the kinase or transcription factor pathways involved in nicotine-induced kidney injury may provide insight into new potential targets for therapy. Mitogen-activated protein (MAP) kinases, including ERK1/2, JNK, and p38, have been implicated in podocyte injury and the progression of chronic kidney diseases (CKD) [32, 33, 52–54]. All these kinases or transcription factors may also be activated by nicotine in various cells [18, 55–57]. We examined the effect of nicotine on the activation of these kinases and factors in podocytes. Our results revealed that nicotine stimulated the phosphorylation of ERK1/2, JNK and p38. Activation of these pathways has been reported to cause podocyte injury including apoptosis, while suppression of them helps to improve the injury [22, 58–60]. Consistent with these reports, in this study we observed that blockade of these kinases with their specific inhibitors significantly reduced nicotine-induced podocyte apoptosis. Recently Kim et al reported that in renal proximal tubular cells (HK-2 cells), nicotine-induced oxidative stress enhanced the phosphorylation of the ERK and JNK signaling pathways, which resulted in the activation of NF-κB signaling pathway and led to apoptosis [18]. In our study, whether the activation of NF-κB signaling pathway is involved in nicotine-induced podocyte apoptosis needs to be investigated in future studies.

Recently, some atypical N-methyl-D-aspartate (NMDA) receptors have attracted the interest of researchers for the involved mechanism in the development of nephropathy [61–64]. These NMDA receptors are expressed throughout the kidney, and sustained activation of these receptors in podocytes contributes to oxidative stress, loss of slit diaphragm proteins, and apoptosis [61, 62]. All these effects are similar to nicotinic receptors as described in our study. In addition, the activation of NMDA receptors induces Ca²⁺ influx via cation channels [61, 62], which can lead to glomerulosclerosis. Since several of the nicotinic receptors assembled by the subunits presenting in podocytes are highly calcium permeable [65–71], we speculate that the podocyte nicotinic receptors may also have this function. All these findings indicate that nicotinic receptors may cause parallel effects in podocytes akin to transduction mechanisms manifested by NMDA receptors.

In conclusion, we have demonstrated that nicotine has the potential to directly threaten the survival of podocytes, which would contribute to chronic kidney injury. The effects of nicotine are mediated through the generation of ROS, and are regulated by JNK, ERK1/2, and p38 pathways. Our study provides insight into new mechanisms involved in nicotine-induced podocyte damage, and highlights some new therapeutic targets for smoking induced kidney injury.

**Author Contributions**

**Conceptualization:** XL.

**Data curation:** XL AM PCS.
Formal analysis: XL AM PCS.
Funding acquisition: PCS.
Investigation: XL RL JME SSMS.
Methodology: XL RL JME SSMS MAS.
Project administration: AM PCS.
Resources: MAS PCS.
Software: XL JME SSMS.
Supervision: XL PCS.
Validation: XL AM PCS.
Visualization: XL RL SSMS AM.
Writing – original draft: XL.
Writing – review & editing: JME SSMS AM PCS.

References
1. Fagerström K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs. 2002; 62 Suppl 2: 1–9.
2. Jain G, Jaimes EA. Nicotine signaling and progression of chronic kidney disease in smokers. Biochem Pharmacol. 2013; 86: 1215–1223. doi: 10.1016/j.bcp.2013.07.014 PMID: 23892062
3. Mercado C, Jaimes EA. Cigarette smoking as a risk factor for atherosclerosis and renal disease: novel pathogenic insights. Curr Hypertens Rep. 2007; 9: 66–72. PMID: 17362674
4. Jaimes EA, Tian RX, Raj L. Nicotine: the link between cigarette smoking and the progression of renal injury? Am J Physiol Heart Circ Physiol. 2007; 292: H76–82. doi: 10.1152/ajpheart.00693.2006 PMID: 16920799
5. Hilleghe HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001; 249: 519–526. PMID: 11422658
6. Pinto-Sietsma SJ, Mulder J, Janssen WM, Hilleghe HL, de Zeeuw D, de Jong PE. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med. 2000; 133: 585–591. PMID: 11033585
7. Halimi JM, Giraudreau B, Vol S, Cacès E, Nivet H, Lebranchu Y, et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int. 2000; 58: 1285–1292. doi: 10.1046/j.1523-1755.2000.00284.x PMID: 10972692
8. Ishizaka N, Ishizaka Y, Toda E, Shimomura H, Koike K, Seki G, et al. Association between cigarette smoking and chronic kidney disease in Japanese men. Hypertens Res. 2008; 31: 485–492. doi: 10.1291/hypres.31.485 PMID: 18497468
9. Dyck RF, Hayward MN, Harris SB; CIRCLE Study Group. Prevalence, determinants and co-morbidities of chronic kidney disease among First Nations adults with diabetes: results from the CIRCLE study. BMC Nephrol. 2012; 13: 57. doi: 10.1186/1471-2369-13-57 PMID: 22776036
10. Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Influence of smoking and obesity on the development of proteinuria. Kidney Int. 2002; 62: 956–962. doi: 10.1046/j.1523-1755.2002.00506.x PMID: 12164878
11. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev. 2009; 89: 73–120. doi: 10.1152/physrev.00015.2008 PMID: 19126755
12. Orth SR, Hallan SI. Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients-absence of evidence or evidence of absence? Clin J Am Soc Nephrol. 2008; 3: 226–236. doi: 10.2215/CJN.03740907 PMID: 18003763
13. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 1996; 382 (6588): 255–257. doi: 10.1038/382255a0 PMID: 8717040

14. Hua P, Feng W, Ji S, Raji L, Jaimes EA. Nicotine worsens the severity of nephropathy in diabetic mice: implications for the progression of kidney disease in smokers. Am J Physiol Renal Physiol. 2010; 299: F732–739. doi: 10.1152/ajprenal.00293.2010 PMID: 20685820

15. Jaimes EA, Tian RX, Joshi MS, Raji L. Nicotine augments glomerular injury in a rat model of acute nephritis. Am J Nephrol. 2009; 29: 319–326. doi: 10.1159/000163593 PMID: 18849602

16. Arany I, Grifoni S, Clark JS, Csongradi E, Maric C, Juncos LA. Chronic nicotine exposure exacerbates acute renal ischemic injury. Am J Physiol Renal Physiol. 2011; 301: F125–133. doi: 10.1152/ajprenal.00041.2011 PMID: 21511693

17. Arany I, Reed DK, Grifoni SC, Chandrasekar K, Booz GW, Juncos LA. A novel USTAT3-dependent mechanism mediates the deleterious effects of chronic nicotine exposure on renal injury. Am J Physiol Renal Physiol. 2012; 301: F722–729. doi: 10.1152/ajprenal.00338.2011 PMID: 22169004

18. Kim CS, Choi JS, Joo SY, Bae EH, Ma SK, Lee J, et al. Nicotine-Induced Apoptosis in Human Renal Proximal Tubular Epithelial Cells. PLoS One. 2016; 11: e0152591. doi: 10.1371/journal.pone.0152591 PMID: 27028622

19. Medapalli RK, He JC, Klotman PE. HIV-associated nephropathy: pathogenesis. Curr Opin Nephrol Hypertens. 2011; 20: 306–311. doi: 10.1097/MNH.0b013e328345359a PMID: 21358326

20. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol. 2002; 13: 3005–3015. PMID: 12444221

21. Saleema MA, O’Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol. 2002; 13: 630–638. PMID: 11856766

22. Lan X, Rai P, Chandel N, Cheng K, Lederman R, Saleema MA, et al. Morphine induces albuminuria by compromising podocyte integrity. PLoS One. 2013; 8: e55748. doi: 10.1371/journal.pone.0055748 PMID: 23555556

23. Lan X, Chen Q, Wang Y, Jia B, Sun L, Zheng J, et al. TNF-α affects human cortical neural progenitor cell differentiation through the autocrine secretion of leukemia inhibitory factor. PLoS One. 2012; 7: e50783. doi: 10.1371/journal.pone.0050783 PMID: 23236394

24. Vashistha H, Husain M, Kumar D, Singhal PC. Tubular cell HIV-1 gp120 expression induces caspase 8 activation and apoptosis. Ren Fail. 2009; 31: 303–312. doi: 10.1080/08860220902780101 PMID: 19462280

25. Lan X, Jhaveri A, Cheng K, Wen H, Saleema MA, Mathieson PW, et al. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am J Physiol Renal Physiol. 2014; 307: F326–336. doi: 10.1152/ajprenal.00647.2013 PMID: 24899058

26. Patel J, Manjappa N, Bhat R, Mehrotra P, Bhaskaran M, Singhal PC. Role of oxidative stress and heme oxygenase activity in morphine-induced glomerular epithelial cell growth. Am J Physiol Renal Physiol. 2003; 285: F861–869. doi: 10.1152/ajprenal.00134.2003 PMID: 12812915

27. Nistala R, Whaley-Connell A, Sowers JR. Redox control of renal function and hypertension. Antioxid Redox Signal. 2008; 10: 2047–2089. doi: 10.1089/ars.2008.2034 PMID: 18821850

28. Susztak K, Raff AC, Schiffer M, Böttiger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006; 55: 225–233. PMID: 16380497

29. Shi JX, Wang QJ, Li H, Huang Q. Silencing of USP22 suppresses high glucose-induced apoptosis, ROS production and inflammation in podocytes. Mol Biosyst. 2016; 12: 1445–1456. doi: 10.1039/c5mb00722d PMID: 26953552

30. Hua W, Huang HZ, Tan LT, Wan JM, Gui HB, Zhao L, et al. CD36 Mediated Fatty Acid-Induced Podocyte Apoptosis via Oxidative Stress. PLoS One. 2015; 10: e0127507. doi: 10.1371/journal.pone.0127507 PMID: 26000608

31. Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, et al. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant. 2011; 26: 2475–2484. doi: 10.1093/ndt/gfq750 PMID: 21220752

32. He JC, Husain M, Sunamoto M, D’Agati VD, Klotman ME, Iyengar R, et al. Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1, 2 pathways. J Clin Invest. 2004; 114: 643–651. doi: 10.1172/JCI21004 PMID: 15343382

33. Koshikawa M, Mukoyama M, Mori K, Suganami T, Sawai K, Yoshika T, et al. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol. 2005; 16: 2690–2701. doi: 10.1681/ASN.2004121084 PMID: 15987752
34. Liu Y, Liang W, Yang Q, Ren Z, Chen X, Zha D, et al. IQGAP1 mediates angiotensin II-induced apoptosis of podocytes via the ERK1/2 MAPK signaling pathway. Am J Nephrol. 2013; 38: 430–444. doi: 10.1159/000355970 PMID: 24247724

35. Agrawal S, Guess AJ, Chanley MA, Smoyer WE. Albumin-induced podocyte injury and protection are associated with regulation of COX-2. Kidney Int. 2014; 86: 1150–1160. doi: 10.1038/ki.2014.196 PMID: 24918154

36. Zheng R, Deng Y, Chen Y, Fan J, Zhang M, Zhong Y, et al. Astragaloside IV attenuates complement membranous attack complex induced podocyte injury through the MAPK pathway. Phytother Res. 2012; 26: 892–896. doi: 10.1002/ptr.3656 PMID: 22086717

37. Li X, He JC. An update: the role of Nephrin inside and outside the kidney. Sci China Life Sci. 2015; 58: 649–657. doi: 10.1007/s11427-015-4844-1 PMID: 25921941

38. Menzel S, Moeller MJ. Role of the podocyte in proteinuria. Pediatr Nephrol. 2011; 26: 1775–1780. doi: 10.1007/s00467-010-1725-5 PMID: 21184239

39. Leeuwis JW, Nguyen TQ, Dendooven A, Kok RJ, Goldschmeding R. Targeting podocyte-associated diseases. Adv Drug Deliv Rev. 2010; 62: 1325–1336. doi: 10.1016/j.addr.2010.08.012 PMID: 20828590

40. Razani-Boroujerdi S, Boyd RT, Davila-Garcia MI, Nandi JS, Mishra NC, Singh SP, et al. T cells express α7-nicotinic acetylcholine receptor subunits that require a functional TCR and leukocyte-specific protein tyrosine kinase for nicotine-induced Ca2+ response. J Immunol. 2007; 179: 2889–2898. PMID: 17709503

41. Charpantier E, Wiesner A, Huh KH, Ogier R, Hoda JC, Allaman G, et al. α7 neuronal nicotinic acetylcholine receptors are negatively regulated by tyrosine phosphorylation and Src-family kinases. J Neurosci. 2005; 25: 9836–9849. doi: 10.1523/JNEUROSCI.3497-05.2005 PMID: 16251431

42. Calderon LE, Liu S, Arnold N, Brekall B, Rollins J, Ndinguri M. Bromoenol lactone attenuates nicotine-induced breast cancer cell proliferation and migration. PLoS One. 2015; 10: e0143277. doi: 10.1371/journal.pone.0143277 PMID: 26588686

43. Al-Wadei MH, Banerjee J, Al-Wadei HA, Schuller HM. Nicotine induces self-renewal of pancreatic cancer stem cells via neurotransmitter-driven activation of sonic hedgehog signalling. Eur J Cancer. 2016; 52: 188–196. doi: 10.1016/j.ejca.2015.10.003 PMID: 26689865

44. Nordman JC, Muldoon P, Clark S, Damaj MI, Kabbani N. The α4 nicotinic receptor promotes CD4+ T-cell proliferation and a helper T-cell immune response. Mol Pharmacol. 2014; 85: 50–61. doi: 10.1124/mol.113.088484 PMID: 24107512

45. Schaal C, Chellappan SP. Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers. Mol Cancer Res. 2014; 12: 14–23. doi: 10.1158/1541-7786.MCR-13-0541 PMID: 24398389

46. Gu Y, Xu W, Nie D, Zhang D, Dai J, Zhao X, et al. Nicotine induces Nme2-mediated apoptosis in mouse testes. Biochem Biophys Res Commun. 2016; 472: 573–579. doi: 10.1016/j.bbrc.2016.03.044 PMID: 26972251

47. Zanetti F, Giacomello M, Donati Y, Carnesecchi S, Frieden M, Barazzzone-Argiroffo C. Nicotine mediates oxidative stress and apoptosis through cross talk between NOX1 and Bcl-2 in lung epithelial cells. Free Radic Biol Med. 2014; 76: 173–184. doi: 10.1016/j.freeradbiom.2014.08.002 PMID: 25151121

48. Zhou X, Sheng Y, Yang R, Kong X. Nicotine promotes cardiomyocyte apoptosis via oxidative stress and altered apoptosis-related gene expression. Cardiology. 2010; 115: 243–250. doi: 10.1159/000301278 PMID: 20339300

49. Schneider NG, Olmstead RE, Franzon MA, Lunell E. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet. 2001; 40: 661–684. doi: 10.2165/00003088-20014009-00003 PMID: 11605715

50. Weber ML, Farooqui M, Nguyen J, Ansonoff M, Pintar JE, Hebbel RP, et al. Morphine induces mesangial cell proliferation and glomerulopathy via kappaoioid receptors. Am J Physiol Renal Physiol. 2008; 294: 1388–1397.

51. Benzing T. Signaling at the slit diaphragm. J Am Soc Nephrol. 2004; 15: 1382–1391. PMID: 15153549

52. Lim AK, Nikolic-Paterson DJ, Ma FY, Ozols E, Thomas MC, Flavell RA, et al. Role of MKK3-p38 MAPK signalling in the development of type 2 diabetes and renal injury in obese db/db mice. Diabetesologia. 2009; 52: 347–358. doi: 10.1007/s00125-008-1215-5 PMID: 1906844
Nicotine enhances invasion and metastasis of human colorectal cancer cells through the nicotinic acetylcholine receptor downstream p38 MAPK signaling pathway. Oncol Rep. 2016; 35: 205–210. doi: 10.3892/or.2015.4363 PMID: 26530054

Shi D, Guo W, Chen W, Fu L, Wang J, Tian Y, et al. Nicotine promotes proliferation of human nasopharyngeal carcinoma cells by regulating α7AChR, ERK, HIF-1α and VEGF/PIGF signaling. PLoS One. 2012; 7: e43898 doi: 10.1371/journal.pone.0043898 PMID: 22952803

Miyamoto Y, Sakai R, Maeda C, Takata T, Ihara H, Tsuchiya Y, et al. Nitric oxide promotes nicotine-triggered ERK signaling via redox reactions in PC12 cells. Nitric Oxide. 2011; 25: 344–349. doi: 10.1016/j.niox.2011.06.006 PMID: 21742048

Hong T, Cui LK, Wen J, Zhang MH, Fan JM. Cordycepin protects podocytes from injury mediated by complements complex C5b-9. Sichuan Da Xue Xue Bao Yi Xue Ban. 2015; 46: 173–178, 227. PMID: 25924424

Saurus P, Kuusela S, Lehtonen E, Hyvönen ME, Ristola M, et al. Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway. Cell Death Dis. 2015; 6: e1752. doi: 10.1038/cddis.2015.125 PMID: 25950482

Zhang YJ, Tian ZL, Yu XY, Zhao XX, Yao L. Activation of integrin β1-focal adhesion kinase-RasGTP pathway plays a critical role in TGF beta1-induced podocyte injury. Cell Signal. 2013; 25: 2769–2779. doi: 10.1016/j.cellsig.2013.08.044 PMID: 24036212

Anderson M, Suh JM, Kim EY, Dryer SE. Functional NMDA receptors with atypical properties are expressed in podocytes. Am J Physiol Cell Physiol. 2011; 300: C22–32. doi: 10.1152/ajpcell.00268.2010 PMID: 20739624

Kim EY, Anderson M, Dryer SE. Sustained activation of N-methyl-D-aspartate receptors in podocytes leads to oxidative stress, mobilization of transient receptor potential canonical 6 channels, nuclear factor of activated T cells activation, and apoptotic cell death. Mol Pharmacol. 2012; 82: 728–737. doi: 10.1124/mol.112.104240 PMID: 27190210

Dryer SE. Glutamate receptors in the kidney. Nephrol Dial Transplant. 2015; 30: 1630–1638. doi: 10.1093/ndt/gfv028 PMID: 25829324

Roshanravan H, Kim EY, Dryer SE. NMDA Receptors as Potential Therapeutic Targets in Diabetic Nephropathy: Increased Renal NMDA Receptor Subunit Expression in Akita Mice and Reduced Nephropathy Following Sustained Treatment With Memantine or MK-801. Diabetes. 2016; 65: 3139–3150. doi: 10.2337/db16-0209 PMID: 27388219

Corradi J, Bouzat C. Understanding the Bases of Function and Modulation of α7 Nicotinic Receptors: Implications for Drug Discovery. Mol Pharmacol. 2016; 90: 288–299. doi: 10.1124/mol.116.1104240 PMID: 27190210

Sciaccaluga M, Moriconi C, Martinello K, Catalano M, Bermudez I, Stitziel JA, et al. Crucial role of nicotinic δ5 subunit variants for Ca2+ fluxes in ventral midbrain neurons. FASEB J. 2015; 29: 3389–3398. doi: 10.1096/fj.14-268102 PMID: 25911614

Lipovsek M, Fierro A, Pérez EG, Boffi JC, Millar NS, Fuchs PA, et al. Tracking the molecular evolution of calcium permeability in a nicotinic acetylcholine receptor. Mol Biol Evol. 2014; 31: 3250–3265. doi: 10.1093/molbev/msu258 PMID: 25193338

Gergalova G, Lykhmus O, Komisarenko S, Skok M. α7 nicotinic acetylcholine receptors control cytochrome c release from isolated mitochondria through kinase-mediated pathways. Int J Biochem Cell Biol. 2014; 49: 26–31. doi: 10.1016/j.biocel.2014.01.001 PMID: 24412630

Tamminäki A, Herder P, Li P, Esch C, Laughlin JR, Aik G, et al. Impact of human D398N single nucleotide polymorphism on intracellular calcium response mediated by α3β4δ5 nicotinic acetylcholine receptors. Neuropharmacology. 2012; 63: 1002–1011. doi: 10.1016/j.neuropharm.2012.07.022 PMID: 22820273

Shen JX, Yakel JL. Nicotinic acetylcholine receptor-mediated calcium signaling in the nervous system. Acta Pharmacol Sin. 2009; 30: 673–680. doi: 10.1038/aps.2009.64 PMID: 19448647

Fucile S. Ca2+ permeability of nicotinic acetylcholine receptors. Cell Calcium. 2004; 35(1): 1–8. PMID: 14670366